Biohaven's Depression Drug BHV-7000 Falls Short in Clinical Trial
Biohaven's (BHVN) experimental depression treatment BHV-7000 didn't meet its primary goal in Phase 2 testing, though some patient subgroups showed promising trends.
/ 11 items
#BHVN↓
Biohaven's BHV-1510 Shows 100% Response Rate in Endometrial Cancer Trial
Biohaven's (BHVN) BHV-1510 cancer drug shows impressive response rates in lung, endometrial, and bladder cancers with fewer side effects than similar treatments.
UBS Downgrades Biohaven on Pipeline Setbacks
UBS cuts Biohaven to Neutral from Buy, lowering the price target to $11 due to multiple R&D and regulatory setbacks and rising competition in its Kv7 program.
FDA Rejects Biohaven's Troriluzole for Rare Neurological Disease, Company Slashes R&D Budget
FDA denies Biohaven's troriluzole approval for spinocerebellar ataxia citing real-world evidence concerns. Company cuts R&D spending 60% and refocuses on three key late-stage programs.
FDA Feedback Rocks uniQure: Gene Therapy for Huntington’s Disease Delayed
UniQure's stock plummeted after the FDA unexpectedly decided that the current clinical trial data for its promising Huntington's disease therapy, AMT-130, is not adequate for immediate marketing application (BLA).